PanTher Therapeutics features treatment platform designed to enhance therapeutic response with minimal side effects.
PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 19, 2021 | Series A | $5.41M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Angel Physicians Fund | — | Series A |